메뉴 건너뛰기




Volumn 262, Issue Part A, 2014, Pages 44-51

Daclizumab (anti-CD25) in multiple sclerosis

Author keywords

Anti CD25; Daclizumab; Immunomodulatory therapy; Monoclonal antibody treatment; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; CD56 ANTIGEN; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ALPHA; PLACEBO; RUXOLITINIB; TOFACITINIB; IL2RA PROTEIN, HUMAN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

EID: 84908617579     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.04.015     Document Type: Review
Times cited : (41)

References (70)
  • 1
    • 37849032623 scopus 로고    scopus 로고
    • Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells
    • Airas L., Saraste M., Rinta S., Elovaara I., Huang Y.H., Wiendl H. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin. Exp. Immunol. 2008, 151(2):235-243.
    • (2008) Clin. Exp. Immunol. , vol.151 , Issue.2 , pp. 235-243
    • Airas, L.1    Saraste, M.2    Rinta, S.3    Elovaara, I.4    Huang, Y.H.5    Wiendl, H.6
  • 4
    • 65249138318 scopus 로고    scopus 로고
    • Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis
    • Bielekova B., Howard T., Packer A.N., Richert N., Blevins G., Ohayon J., Waldmann T.A., McFarland H.F., Martin R. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 2009, 66(4):483-489.
    • (2009) Arch. Neurol. , vol.66 , Issue.4 , pp. 483-489
    • Bielekova, B.1    Howard, T.2    Packer, A.N.3    Richert, N.4    Blevins, G.5    Ohayon, J.6    Waldmann, T.A.7    McFarland, H.F.8    Martin, R.9
  • 7
    • 26044436515 scopus 로고    scopus 로고
    • Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood
    • Bratke K., Kuepper M., Bade B., Virchow J.C., Luttmann W. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. Eur. J. Immunol. 2005, 35(9):2608-2616.
    • (2005) Eur. J. Immunol. , vol.35 , Issue.9 , pp. 2608-2616
    • Bratke, K.1    Kuepper, M.2    Bade, B.3    Virchow, J.C.4    Luttmann, W.5
  • 12
    • 0037029424 scopus 로고    scopus 로고
    • Multiple sclerosis
    • Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359(9313):1221-1231.
    • (2002) Lancet , vol.359 , Issue.9313 , pp. 1221-1231
    • Compston, A.1    Coles, A.2
  • 13
    • 0035499063 scopus 로고    scopus 로고
    • The biology of human natural killer-cell subsets
    • Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol. 2001, 22(11):633-640.
    • (2001) Trends Immunol. , vol.22 , Issue.11 , pp. 633-640
    • Cooper, M.A.1    Fehniger, T.A.2    Caligiuri, M.A.3
  • 15
    • 0038082247 scopus 로고    scopus 로고
    • The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors
    • Della Chiesa M., Vitale M., Carlomagno S., Ferlazzo G., Moretta L., Moretta A. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. Eur. J. Immunol. 2003, 33(6):1657-1666.
    • (2003) Eur. J. Immunol. , vol.33 , Issue.6 , pp. 1657-1666
    • Della Chiesa, M.1    Vitale, M.2    Carlomagno, S.3    Ferlazzo, G.4    Moretta, L.5    Moretta, A.6
  • 16
    • 0024614839 scopus 로고
    • Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat
    • Engelhardt B., Diamantstein T., Wekerle H. Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat. J. Autoimmun. 1989, 2(1):61-73.
    • (1989) J. Autoimmun. , vol.2 , Issue.1 , pp. 61-73
    • Engelhardt, B.1    Diamantstein, T.2    Wekerle, H.3
  • 20
    • 78649826782 scopus 로고    scopus 로고
    • Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved
    • Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 2011, 25(1):37-52.
    • (2011) CNS Drugs , vol.25 , Issue.1 , pp. 37-52
    • Gold, R.1
  • 24
    • 84871152858 scopus 로고    scopus 로고
    • IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells
    • Heninger A.K., Theil A., Wilhelm C., Petzold C., Huebel N., Kretschmer K., Bonifacio E., Monti P. IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells. J. Immunol. 2012, 189(12):5649-5658.
    • (2012) J. Immunol. , vol.189 , Issue.12 , pp. 5649-5658
    • Heninger, A.K.1    Theil, A.2    Wilhelm, C.3    Petzold, C.4    Huebel, N.5    Kretschmer, K.6    Bonifacio, E.7    Monti, P.8
  • 25
    • 79960547202 scopus 로고    scopus 로고
    • Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis
    • Jiang W., Chai N.R., Maric D., Bielekova B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J. Immunol. 2011, 187(2):781-790.
    • (2011) J. Immunol. , vol.187 , Issue.2 , pp. 781-790
    • Jiang, W.1    Chai, N.R.2    Maric, D.3    Bielekova, B.4
  • 27
    • 0029414791 scopus 로고
    • Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development
    • Leonard W.J., Shores E.W., Love P.E. Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development. Immunol. Rev. 1995, 148:97-114.
    • (1995) Immunol. Rev. , vol.148 , pp. 97-114
    • Leonard, W.J.1    Shores, E.W.2    Love, P.E.3
  • 28
    • 17844364666 scopus 로고    scopus 로고
    • Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis
    • Li Z., Lim W.K., Mahesh S.P., Liu B., Nussenblatt R.B. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J. Immunol. 2005, 174(9):5187-5191.
    • (2005) J. Immunol. , vol.174 , Issue.9 , pp. 5187-5191
    • Li, Z.1    Lim, W.K.2    Mahesh, S.P.3    Liu, B.4    Nussenblatt, R.B.5
  • 29
    • 84872790689 scopus 로고    scopus 로고
    • Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy
    • Liao W., Lin J.X., Leonard W.J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38(1):13-25.
    • (2013) Immunity , vol.38 , Issue.1 , pp. 13-25
    • Liao, W.1    Lin, J.X.2    Leonard, W.J.3
  • 34
    • 41949097030 scopus 로고    scopus 로고
    • The biology of interleukin-2
    • Malek T.R. The biology of interleukin-2. Annu. Rev. Immunol. 2008, 26:453-479.
    • (2008) Annu. Rev. Immunol. , vol.26 , pp. 453-479
    • Malek, T.R.1
  • 35
    • 77951828930 scopus 로고    scopus 로고
    • Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
    • Marriott J.J., Miyasaki J.M., Gronseth G., O'Connor P.W. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010, 74(18):1463-1470.
    • (2010) Neurology , vol.74 , Issue.18 , pp. 1463-1470
    • Marriott, J.J.1    Miyasaki, J.M.2    Gronseth, G.3    O'Connor, P.W.4
  • 36
    • 84863410319 scopus 로고    scopus 로고
    • Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis
    • Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin. Immunol. 2012, 142(1):9-14.
    • (2012) Clin. Immunol. , vol.142 , Issue.1 , pp. 9-14
    • Martin, R.1
  • 37
    • 77955506880 scopus 로고    scopus 로고
    • An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells
    • Martin J.F., Perry J.S., Jakhete N.R., Wang X., Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J. Immunol. 2010, 185(2):1311-1320.
    • (2010) J. Immunol. , vol.185 , Issue.2 , pp. 1311-1320
    • Martin, J.F.1    Perry, J.S.2    Jakhete, N.R.3    Wang, X.4    Bielekova, B.5
  • 38
    • 34548133584 scopus 로고    scopus 로고
    • Multiple sclerosis: a complicated picture of autoimmunity
    • McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007, 8(9):913-919.
    • (2007) Nat. Immunol. , vol.8 , Issue.9 , pp. 913-919
    • McFarland, H.F.1    Martin, R.2
  • 43
    • 84864558396 scopus 로고    scopus 로고
    • Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis
    • 145ra106
    • Perry J.S., Han S., Xu Q., Herman M.L., Kennedy L.B., Csako G., Bielekova B. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci. Transl. Med. 2012, 4(145):145ra106.
    • (2012) Sci. Transl. Med. , vol.4 , Issue.145
    • Perry, J.S.1    Han, S.2    Xu, Q.3    Herman, M.L.4    Kennedy, L.B.5    Csako, G.6    Bielekova, B.7
  • 44
    • 84878303057 scopus 로고    scopus 로고
    • Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis
    • Pfender N., Saccardi R., Martin R. Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr. Treat. Options Neurol. 2013, 15(3):270-280.
    • (2013) Curr. Treat. Options Neurol. , vol.15 , Issue.3 , pp. 270-280
    • Pfender, N.1    Saccardi, R.2    Martin, R.3
  • 46
    • 84896722910 scopus 로고    scopus 로고
    • Basiliximab: efficacy and safety evaluation in kidney transplantation
    • Ponticelli C. Basiliximab: efficacy and safety evaluation in kidney transplantation. Expert Opin. Drug Saf. 2014, 13(3):373-381.
    • (2014) Expert Opin. Drug Saf. , vol.13 , Issue.3 , pp. 373-381
    • Ponticelli, C.1
  • 47
    • 77953464476 scopus 로고    scopus 로고
    • Long-term daclizumab therapy in relapsing-remitting multiple sclerosis
    • Rojas M.A., Carlson N.G., Miller T.L., Rose J.W. Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. Ther. Adv. Neurol. Disord. 2009, 2(5):291-297.
    • (2009) Ther. Adv. Neurol. Disord. , vol.2 , Issue.5 , pp. 291-297
    • Rojas, M.A.1    Carlson, N.G.2    Miller, T.L.3    Rose, J.W.4
  • 48
    • 9644265478 scopus 로고    scopus 로고
    • Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody
    • Rose J.W., Watt H.E., White A.T., Carlson N.G. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. 2004, 56(6):864-867.
    • (2004) Ann. Neurol. , vol.56 , Issue.6 , pp. 864-867
    • Rose, J.W.1    Watt, H.E.2    White, A.T.3    Carlson, N.G.4
  • 49
    • 34548142973 scopus 로고    scopus 로고
    • Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results
    • Rose J.W., Burns J.B., Bjorklund J., Klein J., Watt H.E., Carlson N.G. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007, 69(8):785-789.
    • (2007) Neurology , vol.69 , Issue.8 , pp. 785-789
    • Rose, J.W.1    Burns, J.B.2    Bjorklund, J.3    Klein, J.4    Watt, H.E.5    Carlson, N.G.6
  • 50
    • 0027369395 scopus 로고
    • Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
    • Sadlack B., Merz H., Schorle H., Schimpl A., Feller A.C., Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75(2):253-261.
    • (1993) Cell , vol.75 , Issue.2 , pp. 253-261
    • Sadlack, B.1    Merz, H.2    Schorle, H.3    Schimpl, A.4    Feller, A.C.5    Horak, I.6
  • 51
    • 0028783963 scopus 로고
    • Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells
    • Sadlack B., Lohler J., Schorle H., Klebb G., Haber H., Sickel E., Noelle R.J., Horak I. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 1995, 25(11):3053-3059.
    • (1995) Eur. J. Immunol. , vol.25 , Issue.11 , pp. 3053-3059
    • Sadlack, B.1    Lohler, J.2    Schorle, H.3    Klebb, G.4    Haber, H.5    Sickel, E.6    Noelle, R.J.7    Horak, I.8
  • 52
    • 84875218285 scopus 로고    scopus 로고
    • Innate lymphoid cells: from border protection to the initiation of inflammatory diseases
    • Sanos S.L., Diefenbach A. Innate lymphoid cells: from border protection to the initiation of inflammatory diseases. Immunol. Cell Biol. 2013, 91(3):215-224.
    • (2013) Immunol. Cell Biol. , vol.91 , Issue.3 , pp. 215-224
    • Sanos, S.L.1    Diefenbach, A.2
  • 53
    • 79955695969 scopus 로고    scopus 로고
    • Window of opportunity for daclizumab
    • Schluns K.S. Window of opportunity for daclizumab. Nat. Med. 2011, 17(5):545-547.
    • (2011) Nat. Med. , vol.17 , Issue.5 , pp. 545-547
    • Schluns, K.S.1
  • 54
    • 82555171610 scopus 로고    scopus 로고
    • Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis
    • Sheridan J.P., Zhang Y., Riester K., Tang M.T., Efros L., Shi J., Harris J., Vexler V., Elkins J.S. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult. Scler. 2011, 17(12):1441-1448.
    • (2011) Mult. Scler. , vol.17 , Issue.12 , pp. 1441-1448
    • Sheridan, J.P.1    Zhang, Y.2    Riester, K.3    Tang, M.T.4    Efros, L.5    Shi, J.6    Harris, J.7    Vexler, V.8    Elkins, J.S.9
  • 55
    • 17644396349 scopus 로고    scopus 로고
    • Immunology of multiple sclerosis
    • Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
    • (2005) Annu. Rev. Immunol. , vol.23 , pp. 683-747
    • Sospedra, M.1    Martin, R.2
  • 56
    • 78650310810 scopus 로고    scopus 로고
    • The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling
    • Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 2011, 12(1):21-27.
    • (2011) Nat. Immunol. , vol.12 , Issue.1 , pp. 21-27
    • Spits, H.1    Di Santo, J.P.2
  • 58
    • 0019421207 scopus 로고
    • A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells
    • Uchiyama T., Broder S., Waldmann T.A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J. Immunol. 1981, 126(4):1393-1397.
    • (1981) J. Immunol. , vol.126 , Issue.4 , pp. 1393-1397
    • Uchiyama, T.1    Broder, S.2    Waldmann, T.A.3
  • 59
    • 0019445921 scopus 로고
    • A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells
    • Uchiyama T., Nelson D.L., Fleisher T.A., Waldmann T.A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J. Immunol. 1981, 126(4):1398-1403.
    • (1981) J. Immunol. , vol.126 , Issue.4 , pp. 1398-1403
    • Uchiyama, T.1    Nelson, D.L.2    Fleisher, T.A.3    Waldmann, T.A.4
  • 60
    • 0036200407 scopus 로고    scopus 로고
    • The IL-2/IL-15 receptor systems: targets for immunotherapy
    • Waldmann T.A. The IL-2/IL-15 receptor systems: targets for immunotherapy. J. Clin. Immunol. 2002, 22(2):51-56.
    • (2002) J. Clin. Immunol. , vol.22 , Issue.2 , pp. 51-56
    • Waldmann, T.A.1
  • 61
    • 33846868833 scopus 로고    scopus 로고
    • Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey
    • Waldmann T.A. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol. 2007, 27(1):1-18.
    • (2007) J. Clin. Immunol. , vol.27 , Issue.1 , pp. 1-18
    • Waldmann, T.A.1
  • 63
    • 84881481249 scopus 로고    scopus 로고
    • Modulation of IL-2Ralpha with daclizumab for treatment of multiple sclerosis
    • Wiendl H., Gross C.C. Modulation of IL-2Ralpha with daclizumab for treatment of multiple sclerosis. Nat. Rev. Neurol. 2013, 9(7):394-404.
    • (2013) Nat. Rev. Neurol. , vol.9 , Issue.7 , pp. 394-404
    • Wiendl, H.1    Gross, C.C.2
  • 64
    • 0028784289 scopus 로고
    • Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment
    • Willerford D.M., Chen J., Ferry J.A., Davidson L., Ma A., Alt F.W. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995, 3(4):521-530.
    • (1995) Immunity , vol.3 , Issue.4 , pp. 521-530
    • Willerford, D.M.1    Chen, J.2    Ferry, J.A.3    Davidson, L.4    Ma, A.5    Alt, F.W.6
  • 67
    • 77949301468 scopus 로고    scopus 로고
    • Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
    • Wynn D., Kaufman M., Montalban X., Vollmer T., Simon J., Elkins J., O'Neill G., Neyer L., Sheridan J., Wang C., Fong A., Rose J.W. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010, 9(4):381-390.
    • (2010) Lancet Neurol. , vol.9 , Issue.4 , pp. 381-390
    • Wynn, D.1    Kaufman, M.2    Montalban, X.3    Vollmer, T.4    Simon, J.5    Elkins, J.6    O'Neill, G.7    Neyer, L.8    Sheridan, J.9    Wang, C.10    Fong, A.11    Rose, J.W.12
  • 69
    • 60149085254 scopus 로고    scopus 로고
    • A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells
    • Yu A., Zhu L., Altman N.H., Malek T.R. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009, 30(2):204-217.
    • (2009) Immunity , vol.30 , Issue.2 , pp. 204-217
    • Yu, A.1    Zhu, L.2    Altman, N.H.3    Malek, T.R.4
  • 70
    • 33847054267 scopus 로고    scopus 로고
    • Granzyme Kcleaves the nucleosome assembly protein SET to induce single-stranded DNA nicks of targetcells
    • Zhao T., Zhang H., Guo Y., Zhang Q., Hua G., Lu H., Hou Q., Liu H., Fan Z. Granzyme Kcleaves the nucleosome assembly protein SET to induce single-stranded DNA nicks of targetcells. Cell Death Differ. 2007, 14(3):489-499.
    • (2007) Cell Death Differ. , vol.14 , Issue.3 , pp. 489-499
    • Zhao, T.1    Zhang, H.2    Guo, Y.3    Zhang, Q.4    Hua, G.5    Lu, H.6    Hou, Q.7    Liu, H.8    Fan, Z.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.